Available Grant Opportunities


Week of Feb 11th-15th, 2019

Check back often for weekly updates



Internal Funding Opportunities & Limited Submission Grants:


A. Alfred Taubman Medical Research Institute – Innovation Programs: Phenotyping in the Clinical Setting (Award amount variable, rolling deadline).  


The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis. Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease. The institute anticipates investing up to $2.5 million per year to support the funded projects. What are the criteria for funding? Impact on improving the lives of patients; Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment; Potential for future funding by the NIH or other external agencies; Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system; and, Enhanced interactions with basic or other science disciplines (teams). Letter of intent:  Description of the proposed program. Who is going to work together and what will be their roles? Have you worked together in the past? Where do you want to perform this work? What infrastructure is needed to accomplish the goals? Who will you need to partner with to succeed? What are the present barriers to your success? What are your plans for downstream funding? Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful. There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (glwu@umich.edu). We encourage questions. You may contact us with written questions through Grace Wu (glwu@umich.edu). We’re happy to meet with individuals or teams to discuss ideas.


U-M MTRAC Innovation Hub for Advanced Transportation 2019 Full Award ($100,000 award, deadline March 15th, 2019).  https://cfe.umich.edu/mtrac/?mc_cid=e6e0ec6324&mc_eid=658fd7e061  Research Areas: This program targets transportation technologies that address future or poorly met market needs in areas including mobility solutions robotics and autonomy electric vehicle drivetrain/propulsion software/controls/data sensors advanced transportation materials advanced manufacturing processes. Awarded projects are financed through a 12-month grant and mentored by a team of industry experts and investors. Proposals must have clear objectives with well-defined milestones and success metrics. Amount:12-months grant of $100,000. Eligibility: All faculty investigators and postdocs from institutions of higher education, hospital systems, and non-profit research centers in the State of Michigan.​ February 14, 2019: Info Session Webinar at 12:00PM ET Deadline: Full proposal due - March 15, 2019. Contact: Program Director, Eric Petersen (ericp@umich.edu).  More Information: https://cfe.umich.edu/mtrac/ 




California Walnut Commission – Call for Letters of Intent ($500,000 award, Letter of Intent deadline March 18th, 2019). https://proposalcentral.altum.com/GrantOpportunities.asp?GMID=176 The California Walnut Commission (CWC) is dedicated to funding research in a credible and transparent manner that will improve understanding and expand knowledge about the effects of walnut consumption on health-related areas.  The CWC is currently soliciting Letters of Intent (LOI) for human clinical and observational studies in the areas of: Walnuts in gut microbiome function and overall health outcomes such as lipid metabolism or other microbial metabolites; and, Walnuts in body weight, body composition and/or obesity. In addition, CWC is soliciting Letters of Intent (LOI) for a Meta-analysis and/or systematic review on walnuts and cognitive health in humans. The total proposed budget must be no more than $500,000 for the entire project. Letters of Intent are required from all applicants and must be submitted by Monday, March 18, 2019.



  • Pediatric and Primary Care Management of Atopic Dermatitis – Competitive Grant Program ($300,000 award, deadline April 8th, 2019). https://www.pfizer.com/purpose/medical-grants/process  General Area of Interest for this RFP: Through this RFP it is our intent to support educational projects that focus on addressing knowledge and practice gaps specific to the recognition, diagnosis, treatment, and overall care management of AD. The programming should provide a holistic view on AD, including diagnosis, treatment options, efficacy and safety issues, management of application site pain (ASP) for topical agents, treatment pathways recommendations, as well as the psychosocial impact of AD and other quality of life issues. Target Audience: For pediatricians and primary care practitioners, as well as nurse practitioners and physician assistants who are involved in the care and treatment of patients with AD. Individual projects requesting up to $300,000 will be considered.
  • 2019 U.S. Acromegaly ASPIRE Program – Competitive Grant Program ($100,000 award, deadline June 14th, 2019). https://www.pfizer.com/science/collaboration/medical-research-grants  Area of Research Focus: Research projects that will be considered for Pfizer support will advance the medical knowledge of acromegaly disease, its complications and treatment with pegvisomant.  Projects submitted may include: Effects of excess growth hormone in development of acromegaly complications; Laboratory investigations on effects of pegvisomant; and, Clinical outcomes and patient reported outcomes associated with monotherapy or combination therapy including pegvisomant. Individual projects requesting up to $50,000/year for 1 to 2 years will be considered.

EB Research Partnership - Grants Program ($250,000 award, Letter of Intent deadline July 15th, 2019.  https://www.ebresearch.org/applying-for-a-grant.html EB Research Partnership (EBRP), a 501(c)(3) non-profit organization, seeks to award grant funding for research with the potential to lead directly to commercially feasible products and therapies for treating and/or curing Epidermolysis Bullosa (EB). Applicants are invited to submit a Letter of Interest (LOI) which will be evaluated and scored by EBRP’s Scientific Advisory Board (SAB). Please note that EBRP employs a venture philanthropy model. Research projects submitted for review: Should be designed to result in the creation of treatments and/or therapies for the benefit of EB patients. EBRP looks most favorably on research with the aim of commercialization within the next 3-5 years. May relate to re-purposing existing drugs or products to treat EB, if expected to increase EB patients’ quality of life meaningfully. May be intended to provide localized or systemic benefit to EB patients. May involve pre-clinical or clinical trial work. May relate in whole or in part to developing research-enabling tools, such as outcome measurement and database information to accelerate clinical trials. Should not be concerned primarily with basic research into the classifications of EB or open-ended research projects without potential to lead directly to commercially feasible products or therapies to treat and/or cure EB. For example, a project with the goal of identifying that EB causes itch would not be responsive to EBRP’s request for project proposals; however, a project with the goal of creating a commercially viable therapy that meaningfully reduces itch in EB patients would be responsive to EBRP’s request for project proposals. EBRP expects to review applications for future funding cycles semiannually. The application deadline for the next funding cycle is July 15, 2019 at midnight EST.


Cystic Fibrosis Foundation – Advancing Gene Editing Technologies and Tools for Cystic Fibrosis – Research Grant ($200,000 award + 8% IDC’s, deadline March 12th, 2019).  https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Awards-for-Gene-Editing-for-Cystic-Fibrosis/ As an outcome of a CF gene editing workshop held over the summer, the Cystic Fibrosis Foundation announces a Request for Applications (RFA) to identify and support highly meritorious proposals in gene editing that offer potential to repair or circumvent CFTR mutations in individuals with CF.  A key concept that emerged from the workshop was that investigators without experience in CF research would be more inclined to become involved if access to CF tools and reagents, as well as CF knowledge, were available.  To bring new technologies to the CF field, investigators without experience in CF research are encouraged to apply. Proposals will focus on exploring technologies related to gene editing and generating tools for assessing editing.  These include, but are not limited to, studies aimed at: Creating tools, including animal models, cell lines or organoids, that will be generally applicable and facilitate or accelerate development and assessment of various gene editing strategies;  Developing and optimizing novel gene editing technology platforms and strategies to target the CFTR gene locus; Improving our understanding of potential effects of CFTR gene editing on gene and chromatin topology as related to regulation of CFTR expression; Developing and applying assays to assess off-target effects and adverse events of CFTR gene editing in vitro and/or in vivo; Developing biological endpoints and assays for early in vivo efficacy signals of CFTR gene editing; Understanding and developing assays to monitor potential immune responses to gene editing.  This may include responses to the delivery vehicle, cargo, or CFTR protein; Utilizing CF and/or non-CF animal models to address optimal delivery approaches, appropriate cell targets for long-term correction, dosing, safety, and phenotypic correction of CF pathology; Identifying the threshold of CFTR gene editing needed to reach therapeutic relevance; and, Identifying and overcoming barriers for delivery of gene editing cargo into cells relevant to CF.  Funding of up to US$200,000 per year, plus eight percent (8%) indirect costs may be requested for up to three (3) years. Application Deadline: Tuesday, March 12, 2019 at 5:00 PM (ET).


Huntington’s Disease Society of America – HD Human Biology Project 2019 Request for New Proposals ($150,000 award, Letter of Intent deadline May 24th, 2019). https://hdsa.org/hd-research/hd-human-biology-project/ Despite the identification of the gene responsible for Huntington’s disease (HD) over 25 years ago, there are no effective treatments available to patients to modify disease progression. While the identification of the huntingtin gene led to an incredible number of useful animal models to help us better understand HD biology, the most physiologically relevant scientific observations that will guide the research community in the hunt for effective therapies for HD will be those that are recorded in HD patients.  As a result, the Huntington’s Disease Society of America (HDSA) has adopted a patient-centric research strategy to help meet our goal of identifying effective therapies to slow the progression or onset of HD. The HD Human Biology Project is the cornerstone of this strategy. What is This Project? A one or two year grant mechanism to provide support for young scientists to work collaboratively with HD Clinics from around the world. Awards up to $75,000/year ($50,000 salary support and $25,000 research budget). 2019 HD Human Biology Project Letter of Intent: All interested applicants must complete the required administrative information form and upload a completed Letter of Intent (LOI) no later than Friday, May 24th, 2019 at 5:00 (EDT). 


ALS Association – Milton Safenowitz Postdoctoral Fellowship Grant Program ($100,000 award, deadline March 20th, 2019).  http://www.alsa.org/research/our-approach/call-for-abstracts/milton-safenowitz-2019.html The ALS Association is proud to support the development of new scientists through the Milton Safenowitz Postdoctoral Fellowship.

Topics of interest: In this call for applications – we look to fund the most promising new scientists that will improve our understanding of ALS and/or lead to ways to cure ALS, reduce symptoms or prevent their expression, or improve the lives of those impacted by this disease. We will accept applications from all scientific disciplines. This is a general call for all potential postdoctoral fellows with topics of study related to ALS. We are especially interested in Fellowships supporting: Biomarkers studies to discover and validate ALS biomarkers that can facilitate clinical trials, demonstrate biological effect of promising therapeutics, and speed diagnosis. Clinical trial methodology, including ways to increase trial participation, reduce burden and risk for participation, and increase speed and effectiveness. Studies of or methods for drug target identification including animal models, cell models, methods for high throughput screening, etc. Studies that could ultimately stop ALS progression before impairment, including methods for detection and identification of potential therapeutic options. Studies that could ultimately reduce the risk of developing ALS for people with genetic risk factors, including studies of epigenetics, gene-environment interactions, and associated methodologies. Research infrastructure, such as existing ALS repositories and consortia. Fellowships focused on developing new infrastructure must explain how their project complements new infrastructure. Drug development: Preclinical assessment of therapeutics for ALS pre-IND with a likely chance of reaching the clinic within 3 years. Clinical Trials: Fellowships supporting clinical trials, including Phase I through Phase IV. Studies to help people live with ALS, including: Assistive technology: The development of new technology can improve the quality of life for people with ALS and their families to live a more meaningful and productive life. Caregiver and family burden: Fellowships that will document and relieve the impacts of ALS on caregivers and families of people with ALS. Any other proposal with the chance of significantly improving our understanding of ALS or improving the lives of those impacted. The Milton Safenowitz Postdoctoral Fellowship Program Awards: The maximum amount awarded is $50,000 (US) per year for 2 years. Eligibility is limited to those who have an existing postdoctoral fellowship and the support of their mentor.


Children’s Heart Foundation – Call for Research Proposals 2019 ($100,000 award, deadline June 7th, 2019).  The Children’s Heart Foundation is the leading charitable organization dedicated to funding research for congenital heart disease, congenital birth defects and heart defects in babies and young children. Our 2019 Call for Research Proposals is now open! CHF seeks to fund life-saving, life-changing CHD research in clinical cardiology, basic science, population science, and advancement of surgical/interventional techniques, including, but not limited to the following areas: Genetics; Biochemistry; Pharmacology; Devices and procedural research (cardiac catheterization and surgery); Neurodevelopmental and functional outcomes; Quality and policy regarding delivery of care, coverage and access; Maternal environment and modifiable disease impact on fetuses with CHD; Fetal diagnosis and intervention; and, Long-term care of adults with CHDs. No single project may receive more than $100,000 in CHF funds during any calendar year. The deadline to submit an application for the 2019 research funding cycle is Friday, June 7, 2019.